34 related articles for article (PubMed ID: 2059395)
1. Aldosterone antagonism and hypertension.
Conti CR
Clin Cardiol; 2003 May; 26(5):209-10. PubMed ID: 12769246
[No Abstract] [Full Text] [Related]
2. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans.
Laffer CL; Elijovich F; Eckert GJ; Tu W; Pratt JH; Brown NJ
J Am Soc Hypertens; 2014 Jul; 8(7):475-80. PubMed ID: 25064769
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.
Korol S; Mottet F; Perreault S; Baker WL; White M; de Denus S
Medicine (Baltimore); 2017 Dec; 96(48):e8719. PubMed ID: 29310346
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Heran BS; Wong MM; Heran IK; Wright JM
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD003823. PubMed ID: 18843651
[TBL] [Abstract][Full Text] [Related]
5. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Sato A; Suzuki Y; Saruta T
Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
[TBL] [Abstract][Full Text] [Related]
6. Control of vascular changes by renin-angiotensin-aldosterone system in salt-sensitive hypertension.
Zeng ZH; Luo BH; Gao YJ; Su CJ; He CC; Yi JJ; Li N; Lee RM
Eur J Pharmacol; 2004 Oct; 503(1-3):129-33. PubMed ID: 15496307
[TBL] [Abstract][Full Text] [Related]
7. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
8. Value of angiotensin converting enzyme inhibitors in the elderly: the example of perindopril.
Forette F; McClaran J; Delesalle MC; Hervy MP; Bouchacourt P; Henry-Amar M; Santoni JP
Clin Exp Hypertens A; 1989; 11 Suppl 2():587-603. PubMed ID: 2691131
[TBL] [Abstract][Full Text] [Related]
9. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
Bomback AS; Muskala P; Bald E; Chwatko G; Nowicki M
Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
[TBL] [Abstract][Full Text] [Related]
10. Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?
Plouin PF; Battaglia C; Alhenc-Gélas F; Corvol P
Am J Hypertens; 1991 Apr; 4(4 Pt 1):356-62. PubMed ID: 2059395
[TBL] [Abstract][Full Text] [Related]
11. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
12. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
Shimosawa T
Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
